0000000000731354

AUTHOR

Rosemary Ann Barnes

showing 2 related works from this author

Predicting invasive fungal disease due to Candida species in non-neutropenic, critically ill, adult patients in United Kingdom critical care units.

2016

BACKGROUND: Given the predominance of invasive fungal disease (IFD) amongst the non-immunocompromised adult critically ill population, the potential benefit of antifungal prophylaxis and the lack of generalisable tools to identify high risk patients, the aim of the current study was to describe the epidemiology of IFD in UK critical care units, and to develop and validate a clinical risk prediction tool to identify non-neutropenic, critically ill adult patients at high risk of IFD who would benefit from antifungal prophylaxis. METHODS: Data on risk factors for, and outcomes from, IFD were collected for consecutive admissions to adult, general critical care units in the UK participating in t…

0301 basic medicineMalemedicine.medical_specialtyAntifungal AgentsLetterCritical Illness030106 microbiologyPopulationRisk Assessmentlaw.invention03 medical and health sciences0302 clinical medicineMedical microbiologylawRisk FactorsInvasive fungal infectionsSepsisEpidemiologyCandida albicansmedicineHumansCandidiasis InvasiveeducationIntensive care medicineAgedCandidaCandida sppeducation.field_of_studyAdult patientsCritically illbusiness.industryIncidence (epidemiology)IncidenceCandidiasisCandidemia030208 emergency & critical care medicineAntibiotic ProphylaxisMiddle AgedIntensive care unitUnited KingdomIntensive Care UnitsInfectious DiseasesInvasive fungal diseaseFemalebusinessBMC infectious diseases
researchProduct

Prospective study of amphotericin B formulations in immunocompromised patients in 4 European countries

2005

Background. Amphotericin B is a widely used broad-spectrum antifungal agent, despite being associated with significant adverse events, including nephrotoxicity. Methods. The present prospective study collected data on outcomes for 418 adult patients treated consecutively with polyenes in hematology and oncology wards in 20 hospitals in Europe. Results. Patients initially received amphotericin B deoxycholate (62% of patients), liposomal amphotericin B (27%), or other lipid formulations of amphotericin B (11%). Of the patients initially treated with amphotericin B deoxycholate, 36% had therapy switched to lipid formulations of amphotericin B, primarily because of increased serum creatinine le…

AdultMaleMicrobiology (medical)medicine.medical_specialtyAntifungal AgentsRenal functionPolyenesGastroenterologyNephrotoxicityImmunocompromised HostAmphotericin BAmphotericin B deoxycholateInternal medicineAmphotericin BmedicineHumansProspective StudiesAdverse effectProspective cohort studyAgedHematologybusiness.industryMortality rateLength of StayMiddle AgedSurgeryEuropeInfectious DiseasesMycosesFemaleKidney Diseasesbusinessmedicine.drug
researchProduct